Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination

Aline Baldo, Evanthia Galanis, Frédéric Tangy, Philippe Herman

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Attenuated measles virus (MV) is one of the most effective and safe vaccines available, making it attractive candidate vector to prevent infectious diseases. Attenuated MV have acquired the ability to use the complement regulator CD46 as a major receptor to mediate virus entry and intercellular fusion. Therefore, attenuated MV strains preferentially infect and destroy a wide variety of cancer cells making them also attractive oncolytic vectors. The use of recombinant MV vector has to comply with various regulatory requirements, particularly relating to the assessment of potential risks for human health and the environment. The present article highlights the main characteristics of MV and recombinant MV vectors used for vaccination and virotherapy and discusses these features from a biosafety point of view.

Original languageEnglish (US)
Pages (from-to)1102-1116
Number of pages15
JournalHuman Vaccines and Immunotherapeutics
Issue number5
StatePublished - May 3 2016


  • MV Edmonston strains
  • biosafety
  • measles virus (MV)
  • vaccination
  • viral vectors
  • virotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination'. Together they form a unique fingerprint.

Cite this